Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon Jun 07, 2022 3:33pm
216 Views
Post# 34738029

RE:Big Pharma is facing a looming $236 Billion patent cliff

RE:Big Pharma is facing a looming $236 Billion patent cliff
The patents will for sure be interesting as ONC has itself lost 100 patents in the last 5 years and it looks like 60 in just the last 2 months if you compare the investor presentations.
Also Matt Coffey is quoted as saying in a recent conference "We just need the patents to be there at the time we apply for liscensee" which does make me a bit nervous as even though we have composition of matter patent till 2028 (extendable to 2033 but under what circumstances is it extendable and why not just extend it now), they need to have a successful trial and product approval at the time of application so the pace of a registration trial would for sure have to be faster than the current trials. Also how many of the other patents will be lose between now and a phase 3 registration trial.
<< Previous
Bullboard Posts
Next >>